Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
GANX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.89 - $4.04
Previous CloseN/A
Volume74.47K
Average Volume (3M)264.72K
Market Cap
$50.13M
Enterprise Value$48.87M
Total Cash (Recent Filing)$303.32K
Total Debt (Recent Filing)$98.84K
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 07, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding26,525,068
10 Day Avg. Volume281,571
30 Day Avg. Volume264,722
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1124.84
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.94K
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$8.00Price Target Upside323.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Gain Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe first participant has been dosed in the P1b study of GT-02287 in Parkinson's disease, marking a key proof of concept for the program.
Financial PositionThe company also has sufficient capital into 3Q25, funding it through its next key event, the P1b PD data expected in mid-2025.
Preclinical DataGT-02287 has demonstrated restoration of GCase function, a reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, increased dopamine levels, and improved locomotor function in animal models.
Bears Say
Financial PerformanceGain reported 4Q24 and full-year results with a net loss of ($3.3M) and ($20.4M), respectively, ending the period with $10.4M in cash on the balance sheet.
Risks And ChallengesRisks include clinical and/or commercial failure of GT-02287 in GBA1-PD and/or iPD indications, competition, financing, equity dilution and regulatory setbacks.
---
Ownership Overview
4.90% Insiders
1.62% Mutual Funds
3.17% Other Institutional Investors
89.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $0.89 and its highest was $4.04 in the past 12 months.
What is Gain Therapeutics’s market cap?
Gain Therapeutics’s market cap is $50.13M.
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 37 days.
How were Gain Therapeutics’s earnings last quarter?
Gain Therapeutics released its earnings results on Mar 27, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.104.
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 26,525,068 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Gain Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of Gain Therapeutics?
Currently, no hedge funds are holding shares in GANX
---
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (323.28% Upside)
$8.00 (323.28% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 176.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.86%
12-Months-Change
Fundamentals
Return on Equity
-204.95%
Trailing 12-Months
Asset Growth
-34.85%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics, Inc. (GANX) is a biotechnology company operating in the healthcare sector, focusing on discovering and developing novel therapies to treat rare genetic disorders and neurological diseases. The company utilizes its proprietary SEE-Tx platform to identify and optimize allosteric binding sites on proteins, which can be targeted to restore normal function in misfolded proteins, a common cause of many serious diseases.
---
GANX Stock 12 Month Forecast
Average Price Target
$8.00
▲(323.28% Upside)
Technical Analysis
Amicus
―
Ultragenyx Pharmaceutical
―
Blueprint Medicines
―
Oric Pharmaceuticals
―
Pliant Therapeutics
―
Best Analysts Covering GANX
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+18.98%
reiterated a buy rating 14 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +18.98% per trade.
---